

PRESS RELEASE

BRAIN successfully enters into fiscal year 2015/16

Zwingenberg, February 29, 2016: B.R.A.I.N. Biotechnology Research and Information Network AG (“BRAIN AG“; ISIN DE0005203947 / WKN 520394) today published its financial results for the first quarter of fiscal year 2015/16. Accordingly, in the reporting period from October 1, 2015 to December 31, 2015, the BRAIN Group increased its total operating performance by 11 percent, from Euro 6.3m to Euro 7.0m in a year-over-year comparison. This growth was primarily driven by the “BioIndustrial” segment.

The total operating performance of the “BioIndustrial” segment increased by 23 percent to Euro 3.5m in the first quarter of 2015/16, from Euro 2.9m in the previous year period. The enzyme business of the WeissBioTech subsidiary made a significant contribution to this marked increase in revenues. As a result, the share of total Group operating performance of the industrial product business, combined in the “BioIndustrial” segment, increased from 45 percent to 50 percent. The remaining 50 percent were contributed by the “BioScience” segment, representing the collaboration business of BRAIN, where the total operating performance in the first quarter of 2015/16 equally amounted to Euro 3.5m, after a slight increase year-over-year.

The Group operating result (EBIT) declined from Euro -0.5m to Euro -2.1m over the previous year. Adjusted for one-off costs incurred by the initial public offering of BRAIN AG of Euro 0.8m and personnel

Contact:

B·R·A·I·N
Biotechnology Research
And Information Network AG
Dr. Martin Langer
Executive Vice President
Corporate Development
Darmstädter Str. 34-36
64673 Zwingenberg, Germany

Tel.: +49-6251-9331-0
Fax: +49-6251-9331-11
E-Mail: ir@brain-biotech.de
www.brain-biotech.de

expenses resulting from a share-based employee compensation scheme of Euro 0.4m, the adjusted Group EBIT amounted to Euro -0.9m in the first three months of fiscal year 2015/16. Thereof, Euro -0.2m relate to the “BioIndustrial” segment and Euro -0.7m to the “BioScience” segment.

“During all meetings with investors in the run-up to the IPO we set great store by detailing our industrialisation strategy. We will press ahead vigorously with advancing our own product pipeline, which first and foremost benefits our ‘BioIndustrial’ segment. The first quarter figures of the 2015/2016 fiscal year clearly illustrate that we can grow this segment without compromising our successful collaboration business with industrial partners,” says Dr Jürgen Eck, CEO of BRAIN AG.

Key financials (first three months of fiscal year 2015/16)

(in Euro million) ¹	3M 2015/16	3M 2014/15
Total operating performance ²	6.972	6.265
BioScience	3.490	3.453
BioIndustrial	3.518	2.852
Adjustments (consolidation effects)	-0.037	-0.040
EBIT	-2.112	-0.547
Adjusted EBIT ³	-0.900	-0.541
Group result	-2.370	-0.751
Result per share in Euro	-0.18	-0.08
Number of shares	12,861,068	12,725,818
Cash flows from operating activities	-2.289	-1.029
Cash flows from investing activities	-0.348	-0.166
Cash flows from financing activities	1.885	-0.768

- 1) The financial figures of fiscal 2015/16 are comparable only to a limited extent to the values of the previous year, as for the first quarter of FY 2014/15 they only include the financial figures of the WeissBioTech organisations for the months of November and December 2014 due to the acquisition
- 2) Revenues + change in inventories + other income including R&D grants, only comparable to a limited extent
- 3) Adjusted for one-off costs of the IPO and expenses resulting from share-based employee participation plans



More detailed information on the quarterly financial results and the related consolidated financial tables (profit and loss statement, balance sheet, cash flow statement) are available at www.brain-biotech.de/en/investor-relations/financial-publications as part of the interim statement for the three months period ending December 31, 2015.

+++ENDS+++

About BRAIN

BRAIN is one of Europe's leading technology companies in the field of industrial biotechnology, the core discipline of Bioeconomy. As such, BRAIN identifies previously untapped, efficient enzymes, microbial producer organisms or natural substances from complex biological systems that can be put to industrial use. The innovative solutions and products developed by help of this "Toolbox of Nature" are successfully applied in the chemistry, the cosmetics and the food industries. Today, BRAIN's business model is based on two pillars – "BioScience" and "BioIndustrial". The first pillar, "BioScience", comprises its – frequently exclusive – collaboration business with industrial partners. The second pillar "BioIndustrial" comprises the development and commercialisation of BRAIN's own products and active product components. Further information is available at www.brain-biotech.de/en

Disclaimer

This press release contains forward-looking statements. These statements reflect the current views, expectations, and assumptions of the management of BRAIN AG and are based on information currently available to the management. Forward-looking statements are not guarantees of future performance and involve known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. There are numerous factors which could influence the future performance by and future developments at BRAIN AG and the BRAIN group of companies. Such factors include, but are not limited to, changes in the general economic and competitive environment, risks associated with capital markets, currency exchange rate fluctuations, changes in international and national laws and regulations, in particular with respect to tax laws and regulations, and other factors. BRAIN AG does not undertake any obligation to update or revise any forward-looking statements.